# Batch Record: Definition, Process, and Best Practices

## Introduction to Batch Records

A batch record is the complete, documented history of the manufacture of a single batch of a pharmaceutical, biologic, or biotechnological product. It captures every relevant action, measurement, observation, and deviation that occurred during production, from the initial weighing of raw materials to the final release of the finished product. In regulated industries, the batch record is not merely a convenience—it is a legal and regulatory requirement that demonstrates the product was manufactured under controlled conditions and in accordance with approved specifications.

### Definition and Purpose

The batch record serves two fundamental purposes. First, it provides a contemporaneous, step-by-step account of how a product was made, allowing any qualified reviewer to reconstruct the manufacturing process exactly as it occurred. Second, it provides the evidentiary basis for product release: without a complete and accurate batch record, a batch cannot be released for distribution, regardless of how well the product performs in quality control testing.

In bioprocessing, the batch record takes on additional significance because biological systems are inherently variable. Unlike small-molecule synthesis, where chemical reactions follow predictable stoichiometry, cell culture performance depends on cell line behavior, media composition, environmental conditions, and operator technique. The batch record documents these variables, enabling investigators to trace any product quality issue back to specific process conditions. This traceability is essential for root cause analysis, [process validation](/knowledge/molecular-biology/process-validation), and continuous improvement.

### Regulatory Context (GMP, FDA, EMA)

Batch records are mandated under Good Manufacturing Practice (GMP) regulations enforced by regulatory authorities worldwide. In the United States, the Food and Drug Administration (FDA) requires batch records under 21 CFR Part 211.188, which specifies that a complete batch record must include information on the batch or lot number, the date of manufacture, the identity and quantity of each component used, the equipment used, the in-process and laboratory control results, and the signatures of the persons performing and supervising each significant step.

The European Medicines Agency (EMA) imposes equivalent requirements under EudraLex Volume 4, the EU Guidelines for Good Manufacturing Practice. Chapter 4 of these guidelines addresses documentation, stating that batch records must be prepared and processed to ensure that the history of each batch can be determined. The International Council for Harmonisation (ICH) Q7 guideline, which covers GMP for active pharmaceutical ingredients, further specifies that batch records should include the batch number, the dates and times of each step, the names of operators, and the results of all tests and inspections.

The regulatory stakes are high. Batch record deficiencies are among the most frequently cited observations in FDA Form 483 inspections and warning letters. Common citations include incomplete data entry, missing signatures, undocumented deviations, and discrepancies between the master batch record and the executed batch record. These findings can result in import alerts, consent decrees, or product recalls. Consequently, batch record management is not a documentation exercise—it is a critical compliance function that directly affects market access and patient safety.

## Types of Batch Records

The term "batch record" encompasses two distinct document types that serve different functions in the manufacturing lifecycle. Understanding the distinction between them is essential for anyone working in [GMP manufacturing](/knowledge/molecular-biology/gmp-manufacturing).

### Master Batch Record (MBR)

The Master Batch Record (MBR) is the approved, controlled template that defines how a product is to be manufactured. It is the authoritative source of instructions, specifying the exact materials, equipment, parameters, and procedures required for each batch. The MBR is product-specific and version-controlled; any change to the manufacturing process must be reflected in an updated MBR that undergoes formal review and approval before implementation.

The MBR includes the complete bill of materials, detailed step-by-step instructions, in-process control specifications, sampling plans, and acceptance criteria. It also specifies the equipment to be used, the facility areas where operations will occur, and any special precautions or environmental controls required. In bioprocessing, the MBR typically includes critical process parameters (CPPs) such as temperature setpoints, pH ranges, dissolved oxygen levels, agitation rates, and culture durations, along with the corresponding critical quality attributes (CQAs) that must be met.

The MBR is not a working document—it is the reference against which the executed batch record is compared. It must be approved by quality assurance (QA) and maintained under document control, with a clear revision history that documents all changes and the rationale for each change.

### Executed Batch Record (EBR)

The Executed Batch Record (EBR) is the completed, filled-in version of the MBR for a specific batch. It contains all the actual data recorded during manufacturing: the measured values, the observations, the equipment used, the operators involved, and the results of all in-process and release testing. The EBR is created by reproducing the MBR and adding the required data fields, which are then completed in real time as manufacturing proceeds.

The EBR serves as the definitive record of what actually happened, as opposed to what was planned. It is reviewed after manufacturing to confirm that all steps were performed as specified, all parameters were within acceptable ranges, and all deviations were properly documented and investigated. The EBR is the primary document used in batch disposition decisions—the determination of whether a batch is released, rejected, or placed on hold pending further investigation.

In practice, the EBR is often assembled from multiple sources: the completed MBR pages, equipment printouts, chart recorders, laboratory test results, and deviation reports. The completeness and accuracy of the EBR are paramount, as any gap in the record creates uncertainty about the batch's quality and can delay or prevent release.

## Key Components of a Batch Record

A well-constructed batch record contains several essential sections, each serving a specific purpose in documenting the manufacturing history. The following components are standard across the industry, though the specific format varies between paper and electronic systems.

### Product and Version Information

Every batch record begins with identifying information: the product name, the batch or lot number, the manufacturing date, and the MBR version number that served as the template. This section also includes the intended batch size, the expiry date, and the storage conditions for the finished product. In bioprocessing, the batch record should also reference the specific cell line or working cell bank used, as this information is critical for traceability. For products derived from [cell line development](/knowledge/molecular-biology/cell-line-development), the cell bank passage number and viability data at the time of inoculation should be recorded.

### Bill of Materials and Raw Materials

The bill of materials (BOM) lists every component used in the manufacturing process, including raw materials, intermediates, solvents, reagents, and packaging components. For each item, the BOM specifies the required quantity, the unit of measure, and the specific material grade or specification. The batch record must also capture the actual quantities used, the lot numbers of each material, and the results of any incoming material testing or verification.

In bioprocessing, the BOM includes [cell culture media](/knowledge/diagnostics/microbiology/cell-culture-media-a-guide-to-selection-and-optimization) components, supplements, buffers, and process aids. For example, a typical fed-batch [monoclonal antibody production](/knowledge/molecular-biology/monoclonal-antibody-production) process might include a basal medium such as DMEM/F12, a feed supplement containing concentrated glucose and amino acids, and buffers such as phosphate-buffered saline (PBS) at pH 7.4 for intermediate steps. Each of these must be documented with its lot number and the certificate of analysis (COA) reference. The BOM also includes single-use consumables such as bioreactor bags, filters, and tubing assemblies, which must be traceable to their manufacturing lots.

### Equipment and Facility Details

This section documents the specific equipment used for each unit operation, including the equipment identification number, the location, and the calibration status. For critical equipment, the batch record should capture the last calibration date and the next due date. In bioprocessing, this includes bioreactors, centrifuges, chromatography systems, filtration skids, and filling lines.

The facility details include the manufacturing suite, the room classification (e.g., ISO 7 or ISO 8 for aseptic processing areas), and any environmental monitoring data collected during the batch. For example, a batch record for a sterile biologic might require documentation of viable and non-viable particle counts in the filling suite, surface contamination monitoring results, and operator gowning qualifications.

### Step-by-Step Instructions

The core of the batch record is the sequential list of manufacturing instructions. Each step includes the operation to be performed, the equipment to be used, the critical process parameters to be maintained, and the acceptance criteria to be met. The instructions must be written with sufficient detail that a trained operator can perform the task without ambiguity.

For a typical upstream process, the steps might include:

1. Thaw a vial of the working cell bank in a 37°C water bath for 2–3 minutes.
2. Inoculate the contents into a 125 mL shake flask containing 50 mL of growth medium (DMEM/F12 supplemented with 10% fetal bovine serum).
3. Incubate at 37°C, 5% CO₂, with shaking at 120 rpm for 72 hours.
4. Expand the culture through a series of seed trains: 1 L shake flask, then a 5 L bioreactor, then a 50 L bioreactor, maintaining a seeding density of 0.3 × 10⁶ cells/mL.
5. Transfer the culture to the production bioreactor (500 L working volume) and initiate fed-batch operation with a glucose feed of 5 g/L/day and a temperature shift from 37°C to 33°C at 48 hours post-inoculation.

Each step requires a signature or electronic authentication from the operator and, where specified, from a second person who verifies the action.

### In-Process Control and Sampling

This section specifies the sampling points, the tests to be performed, and the acceptance criteria for in-process controls (IPCs). In bioprocessing, IPCs include cell density and viability measurements (e.g., using a hemocytometer or an automated cell counter), metabolite analysis (glucose, lactate, glutamine, ammonia), pH and dissolved oxygen measurements, and product titer determinations by methods such as protein A HPLC or ELISA.

The batch record must include the results of each IPC test, the identity of the analyst, and the date and time of sampling. Any out-of-specification (OOS) result must be documented and flagged for investigation. The batch record should also specify the sampling frequency—for example, daily cell counts and metabolite measurements during the exponential growth phase, with more frequent sampling during the production phase.

### Review and Approval Signatures

The final section of the batch record captures the review and approval chain. The production supervisor reviews the record to confirm that all steps were completed and all data were recorded. The quality control (QC) unit reviews the test results and confirms that all specifications were met. Finally, the quality assurance (QA) unit performs a comprehensive review and makes the disposition decision—release, reject, or hold.

Each reviewer must sign and date the record, and any discrepancies or unresolved issues must be documented. In an electronic system, signatures are captured through secure electronic authentication that complies with 21 CFR Part 11 requirements.

## The Batch Record Process

The batch record lifecycle extends from the initial creation of the MBR through the execution, review, and archival of the EBR. Each phase has specific requirements and best practices.

### Creating the Master Batch Record

The MBR is created during process development and technology transfer. It is drafted by the manufacturing science and technology (MSAT) group or the process development team, based on the data generated during scale-up studies. The draft MBR is reviewed by manufacturing, quality control, and quality assurance before approval.

The MBR must be written with precision. Each instruction should specify the exact action, the equipment, the materials, and the acceptance criteria. For example, rather than stating "adjust pH," the MBR should state "adjust pH to 7.2 ± 0.1 using 1 N sodium hydroxide or 1 N hydrochloric acid, with continuous stirring at 200 rpm." The MBR should also specify the maximum allowable time for each step, the required environmental conditions, and any safety precautions.

Version control is critical. Each revision of the MBR must be numbered, dated, and accompanied by a summary of changes. The revision history should explain the rationale for each change—for example, "Revised to extend the culture duration from 12 to 14 days based on increased product titer observed in the scale-up study." Obsolete versions must be withdrawn from circulation and archived.

### Executing the Batch Record

Execution begins when manufacturing personnel reproduce the MBR to create the EBR for a specific batch. In a paper system, this involves photocopying the MBR and attaching the data entry forms. In an electronic system, the EBR is generated automatically from the MBR template, with the batch number and date pre-populated.

During execution, operators record data in real time. This is a regulatory requirement—data must be entered at the time the action is performed, not reconstructed later. In a paper system, entries are made in permanent ink, and errors are corrected by striking through the incorrect entry with a single line, writing the correct value, initialing, and dating the correction. In an electronic system, the audit trail automatically captures the original entry, the correction, the person making the correction, and the time of the change.

Deviations that occur during execution must be documented immediately. A deviation is any departure from the approved instructions, whether planned (e.g., a temporary change in a process parameter) or unplanned (e.g., equipment failure). The deviation must be described in the batch record, and a deviation report must be initiated with an impact assessment.

### Review and Disposition

After manufacturing is complete, the EBR undergoes a multi-stage review. The first review is performed by the production supervisor, who verifies that all steps were completed, all data were recorded, and all signatures are present. The second review is performed by quality control, which confirms that all test results meet specifications and that any OOS results have been properly investigated.

The final review is performed by quality assurance, which conducts a comprehensive assessment of the entire record. QA verifies that the EBR matches the MBR, that all deviations have been investigated and closed, and that all supporting documents (e.g., equipment logs, environmental monitoring reports, cleaning records) are present and consistent. Based on this review, QA makes the disposition decision: release, reject, or hold.

### Archival and Retention

Once the disposition decision is made, the EBR is archived. Regulatory requirements specify retention periods: the FDA requires that batch records be retained for at least one year after the expiry date of the batch, or for at least five years if the product has no expiry date. The EMA has similar requirements under EudraLex Volume 4. In practice, most companies retain batch records for much longer—often 10 to 15 years—to support regulatory inspections, product liability claims, and long-term trend analysis.

Archival must ensure that records are protected from damage, loss, and unauthorized access. Paper records must be stored in a controlled environment with fire protection and limited access. Electronic records must be backed up regularly, with the backup media stored in a separate location. The archival system must be able to retrieve any record within a reasonable time frame—typically within 24 to 48 hours—in response to a regulatory inspection.

## Electronic Batch Records (EBR) vs. Paper

The transition from paper to electronic batch records is one of the most significant changes in pharmaceutical manufacturing documentation. Electronic batch records offer substantial advantages but also introduce new challenges in validation and compliance.

### Advantages of EBR

Electronic batch records eliminate many of the failure modes inherent in paper systems. Data entry is automated where possible—for example, equipment sensors can feed pH, temperature, and dissolved oxygen readings directly into the EBR, eliminating transcription errors. Required fields can be enforced, preventing the submission of incomplete records. Signatures can be captured electronically with secure authentication, and the audit trail automatically records who did what, when, and why.

EBR systems also enable real-time visibility into batch status. Managers can monitor the progress of a batch from any location, and quality assurance can review data as it is generated rather than waiting for the completed record. This enables earlier detection of problems and faster decision-making. For example, if a bioreactor temperature drifts outside the specified range, the EBR system can alert the operator and the supervisor immediately, rather than discovering the excursion hours later during the review.

The searchability and analyzability of electronic data are additional advantages. Batch data can be aggregated across multiple batches to support trend analysis, process capability studies, and [batch effect removal](/knowledge/molecular-biology/batch-files) in analytical data. This is particularly valuable in bioprocessing, where subtle changes in process performance can have significant effects on product quality.

### Challenges and Validation

The primary challenge with EBR systems is validation. Under 21 CFR Part 11, electronic records and electronic signatures must be validated to ensure accuracy, reliability, and consistent performance. This requires a comprehensive validation package, including a user requirements specification, a functional requirements specification, a risk assessment, installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ).

The validation effort is substantial and requires specialized expertise. The system must be tested to confirm that it correctly enforces workflow rules, that the audit trail is complete and tamper-evident, that electronic signatures are unique and non-repudiable, and that data is securely stored and backed up. The validation must also demonstrate that the system can handle the required data volume and that it performs reliably under peak load conditions.

Another challenge is the management of change. Any modification to the EBR system—whether a software upgrade, a configuration change, or a new workflow—requires change control and, in many cases, revalidation. This can slow down the implementation of improvements and requires a disciplined approach to system governance.

### Hybrid Approaches

Many companies operate hybrid systems, using electronic batch records for some parts of the process and paper for others. For example, the MBR may be maintained electronically, while the EBR is executed on paper. Or, the upstream cell culture process may use an EBR, while the downstream purification process uses paper records.

Hybrid approaches can be pragmatic, but they introduce their own challenges. The interface between the electronic and paper systems must be clearly defined, and data must be reconciled between the two. For example, if a paper record captures a critical process parameter that is also monitored electronically, the two values must be consistent. Discrepancies between paper and electronic data are a common finding in regulatory inspections.

The trend is clearly toward fully electronic systems, driven by the advantages in data integrity, efficiency, and analyzability. However, the transition requires careful planning, substantial investment, and a robust validation program. Companies that are considering the transition should conduct a thorough gap assessment, develop a detailed implementation plan, and allocate sufficient resources for validation and training.

## Common Errors and Pitfalls in Batch Records

Despite the critical importance of batch records, errors and omissions remain common in practice. Understanding the most frequent failure modes is essential for developing effective prevention strategies.

### Data Integrity Issues

Data integrity is the foundation of batch record credibility, and it is the area where regulatory scrutiny is most intense. The FDA's data integrity guidance (issued in 2018) emphasizes the ALCOA principles: data must be Attributable, Legible, Contemporaneous, Original, and Accurate.

Common data integrity failures include:

- **Backdating or predating entries**: Recording data after the fact, or entering a date that does not match the actual time of the action.
- **Transcription errors**: Copying data from one document to another incorrectly, such as recording a pH of 7.2 when the actual reading was 7.4.
- **Unattributed entries**: Data entered without a clear indication of who made the entry.
- **Data fabrication**: Recording results that were never actually obtained. This is the most serious violation and can result in criminal prosecution.
- **Incomplete audit trails**: In electronic systems, the audit trail may be disabled or incomplete, allowing changes to be made without detection.

Prevention strategies include real-time data entry, automated data capture where possible, regular audits of batch records, and a culture that emphasizes data integrity as a core value. Training should reinforce that data integrity is not optional and that shortcuts are never acceptable.

### Deviation Handling

Deviations are inevitable in bioprocessing, but the way they are handled can make the difference between a minor issue and a major compliance problem. Common pitfalls include:

- **Failure to document deviations**: Operators may not recognize that an action constitutes a deviation, or they may be reluctant to document it for fear of consequences.
- **Incomplete deviation descriptions**: The deviation is documented, but the description is vague—for example, "temperature was out of range" without specifying the actual temperature, the duration of the excursion, or the impact on the product.
- **Delayed investigation**: The deviation is documented, but the investigation is not initiated promptly, allowing critical evidence to be lost.
- **Inadequate impact assessment**: The investigation concludes that the deviation had no impact on product quality, but the rationale is not supported by data.

Effective deviation management requires a just culture where operators are encouraged to report deviations without fear of punishment, a robust investigation process that identifies root causes, and a corrective and preventive action (CAPA) system that ensures lessons learned are implemented.

### Training and Human Error

Many batch record errors trace back to human error, which is often the result of inadequate training or poorly designed procedures. Common issues include:

- **Unclear instructions**: The MBR is ambiguous, allowing different operators to interpret the same instruction differently.
- **Insufficient training**: Operators are not adequately trained on the MBR or the EBR system before they are required to execute a batch.
- **Fatigue and workload**: Long shifts and high workloads increase the likelihood of errors.
- **Poorly designed forms**: Paper forms with cramped spaces or confusing layouts encourage errors and omissions.

Prevention strategies include clear and unambiguous MBR instructions, comprehensive training programs with documented proficiency assessments, reasonable shift schedules, and well-designed forms that provide adequate space for data entry and clear prompts for required information.

## Best Practices for Batch Record Management

Effective batch record management requires a systematic approach that addresses the entire lifecycle, from MBR design to EBR archival. The following best practices are drawn from industry experience and regulatory expectations.

### Clarity and Unambiguity

The MBR must be written so that a trained operator can perform every step without ambiguity. This requires precise language, specific values, and clear acceptance criteria. Avoid vague terms such as "approximately," "about," or "as needed." Instead, specify exact ranges and conditions.

For example, rather than "add the feed solution slowly," write "add the feed solution at a rate of 10 mL/min using a peristaltic pump set to 15 rpm." Rather than "harvest when the viability drops," write "harvest when the viability falls below 60%, as measured by the Vi-CELL XR cell counter, or at 14 days post-inoculation, whichever occurs first."

The MBR should also include visual aids where helpful, such as diagrams of equipment setups or photographs of expected appearances. This is particularly useful for operations that are difficult to describe in words, such as the proper placement of a probe or the correct orientation of a filter.

### Real-Time Data Entry

Data must be entered into the batch record at the time the action is performed. This is a regulatory requirement and a fundamental principle of data integrity. Real-time entry ensures that the data reflects what actually happened, not what the operator remembers or reconstructs later.

In a paper system, this means having the batch record available at the point of use, with a clipboard or a writing surface. In an electronic system, it means having terminals or mobile devices available in the manufacturing area, with the EBR system accessible and responsive.

Real-time entry also applies to equipment data. Chart recorders and data acquisition systems must be checked and verified at the time of the operation, not after the fact. If an automated system records data, the operator should verify that the system is functioning correctly and that the data is being captured.

### Effective Review and QA

The review process is the last line of defense against errors and omissions. An effective review is thorough, systematic, and documented. The reviewer should check the EBR against the MBR, line by line, to confirm that every step was performed as specified.

The review should also verify the consistency of the data. For example, if the EBR shows a cell count of 5 × 10⁶ cells/mL at inoculation, the reviewer should confirm that this is consistent with the expected seeding density and the measured viability. If the EBR shows a pH of 7.2 at a particular time point, the reviewer should confirm that this is consistent with the pH readings before and after that time point.

QA review should include a risk-based approach, focusing on the critical process parameters and critical quality attributes. The reviewer should also verify that all deviations have been investigated and that the investigations have been closed with appropriate actions.

### Continuous Improvement

Batch record management is not a static function. The MBR should be reviewed periodically to identify opportunities for improvement, and the EBR review process should be analyzed to identify recurring issues. Trend analysis of batch data can reveal process drift, equipment degradation, or operator training gaps.

For example, if multiple batches show a gradual decline in product titer, the trend may indicate a problem with the cell line, the media, or the process conditions. If multiple batches show the same deviation—such as a temperature excursion during a particular step—the trend may indicate a problem with the equipment or the procedure.

Continuous improvement also applies to the batch record system itself. Feedback from operators, reviewers, and quality assurance should be collected and used to improve the MBR format, the EBR system, and the training program. The goal is to create a system that is both compliant and efficient, minimizing the burden on manufacturing personnel while maximizing the quality and completeness of the record.

## Conclusion and Practical Summary

Batch records are the backbone of pharmaceutical and biotechnological manufacturing quality. They provide the documented evidence that a product was manufactured under controlled conditions, in accordance with approved specifications, and with the required level of quality. The master batch record defines how a product should be made, while the executed batch record documents what actually happened during manufacturing.

The transition from paper to electronic batch records offers significant advantages in data integrity, efficiency, and analyzability, but it requires careful validation and change management. Regardless of the format, the fundamental principles remain the same: data must be attributable, legible, contemporaneous, original, and accurate.

Common errors in batch records—data integrity issues, inadequate deviation handling, and human error—can be prevented through clear instructions, real-time data entry, effective review, and continuous improvement. The investment in robust batch record management is justified by the regulatory, operational, and patient safety benefits.

## Frequently Asked Questions

### What is a batch record?

A batch record is the complete, documented history of the manufacture of a single batch of a pharmaceutical or biotechnological product. It includes all the data, observations, and actions that occurred during manufacturing, from raw material weighing to final product release. The batch record provides the evidence that the product was manufactured under controlled conditions and in accordance with approved specifications.

### What is the difference between a master batch record and an executed batch record?

The master batch record (MBR) is the approved, controlled template that defines how a product is to be manufactured. It specifies the materials, equipment, instructions, and acceptance criteria. The executed batch record (EBR) is the completed, filled-in version of the MBR for a specific batch, containing all the actual data recorded during manufacturing. The MBR is the plan; the EBR is the record of what actually happened.

### Why are batch records important in bioprocessing?

Batch records are important in bioprocessing because biological systems are inherently variable, and the batch record documents the specific conditions under which each batch was produced. This traceability is essential for root cause analysis, [process validation](/knowledge/molecular-biology/process-validation), and continuous improvement. Batch records are also a regulatory requirement under GMP regulations, and deficiencies in batch records can result in regulatory action, product recalls, or loss of market access.

### What are the key components of a batch record?

The key components of a batch record include product and version information, the bill of materials and raw materials, equipment and facility details, step-by-step instructions, in-process control and sampling results, and review and approval signatures. Each component serves a specific purpose in documenting the manufacturing history and supporting the batch disposition decision.

### What is an electronic batch record (EBR)?

An electronic batch record (EBR) is a batch record that is created, executed, and reviewed using an electronic system, rather than on paper. EBR systems automate data capture, enforce required fields, and provide a secure audit trail that complies with 21 CFR Part 11. EBRs offer advantages in data integrity, efficiency, and analyzability, but they require validation and careful change management.

### How long must batch records be retained?

The FDA requires that batch records be retained for at least one year after the expiry date of the batch, or for at least five years if the product has no expiry date. The EMA has similar requirements under EudraLex Volume 4. In practice, most companies retain batch records for 10 to 15 years to support regulatory inspections, product liability claims, and long-term trend analysis.

### What are common mistakes in batch record completion?

Common mistakes in batch record completion include incomplete data entry, transcription errors, missing signatures, undocumented deviations, and data integrity issues such as backdating or unattributed entries. These mistakes can be prevented through clear instructions, real-time data entry, effective review, and comprehensive training.

## Key Takeaways

- Batch records are the complete, documented history of a batch's manufacture and are required under GMP regulations enforced by the FDA, EMA, and other regulatory authorities.
- The master batch record (MBR) defines the approved manufacturing process, while the executed batch record (EBR) documents what actually occurred during a specific batch.
- Key components of a batch record include product information, bill of materials, equipment details, step-by-step instructions, in-process controls, and review signatures.
- Electronic batch records offer significant advantages in data integrity and efficiency but require validation under 21 CFR Part 11 and careful change management.
- Data integrity is the foundation of batch record credibility, governed by the ALCOA principles: Attributable, Legible, Contemporaneous, Original, and Accurate.
- Common errors—including incomplete data, transcription mistakes, and inadequate deviation handling—can be prevented through clear instructions, real-time data entry, and effective QA review.
- Batch records must be retained for at least one year after product expiry (or five years if no expiry date), though most companies retain them for 10–15 years.

## Further Reading

- NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee, NIH CIT Consortium. *Purified Human Pancreatic Islets (PHPI) Master Production Batch Record: A Standard Operating Procedure of the NIH Clinical Islet Transplantation Consortium*. CellR4-- repair, replacement, regeneration, & reprogramming. 2014. [PubMed 30581890](https://pubmed.ncbi.nlm.nih.gov/30581890/)
- NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee, NIH CIT Consortium. *Purified Human Pancreatic Islets Master Production Batch Record, Part 1 University of Illinois, Chicago & University of Miami (Product Codes PHPI-A-01, PHPI-E-01, PHPI-L-01)*. CellR4-- repair, replacement, regeneration, & reprogramming. 2017. [PubMed 30613744](https://pubmed.ncbi.nlm.nih.gov/30613744/)
- NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee, NIH CIT Consortium. *Purified Human Pancreatic Islets Master Production Batch Record, Part 1 University of Illinois, Chicago & University of Miami (Product Codes PHPI-A-01 & PHPI-L-01)*. CellR4-- repair, replacement, regeneration, & reprogramming. 2017. [PubMed 30613752](https://pubmed.ncbi.nlm.nih.gov/30613752/)
- Janssen W. *[Data management](/blog/guides/data-management-basics-principles-processes-and-best-practices) in the cell therapy production facility: the batch process record (BPR)*. Cytotherapy. 2008. [PubMed 18418768](https://doi.org/10.1080/14653240802020399)

## Related Clinical & Scientific Guides

* [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway)
* [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor)
* [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)